Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Experience of trifluridine/tipiracil and regorafenib in metastatic colorectal cancer.

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-066
  • By: MORENO HERRERA, ADRIANA ()
  • Co-author(s): Dra. ALBA SALGUERO OLID, FARMACIA (HOSPITAL PUNTA EUROPA, ALGECIRAS, Spain)
    Dra. ADRIANA MORENO HERRERA, FARMACIA (HOSPITAL PUNTA EUROPA, ALGECIRAS, Spain)
    Dra. ISABEL MUÑOZ GÓMEZ-MILLÁN, FARMACIA (HOSPITAL PUNTA EUROPA, ALGECIRAS, Spain)
    Dr. ALBERTO SORIA MARTÍN, FARMACIA (HOSPITAL PUNTA EUROPA, ALGECIRAS, Spain)
  • Abstract:

    Background information
    Trifluridine/tipiracil and regorafenib have been approved for the treatment of adult patients with metastatic colorectal cancer (mCRC) who are refractory to or are not considered candidates for current standard chemotherapy.
    Purpose
    To describe effectiveness and safety of trifluridine/tipiracil and regorafenib after..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses